MIRAMAR, FL, June 09, 2022 (GLOBE NEWSWIRE) — Stemtech Corporation (“Stemtech”) (OTCQB:STEK), an innovative nutraceutical company and a pioneer in the field of ADVANCELLS stem cell nutrition, announced today that Ana Groenewold, an Independent Business Partner from Mexico, has attained the high rank of Chairman’s Club Director in May. This coincided with the GLD RSH 90-Day Promotion period where sales and recruitment reached a record 2022 May.
“Ana is a very dedicated and determined person who set her sights on becoming a Chairman’s Club Director and excitedly attained this high rank in May” says John W. Meyer, President & COO of Stemtech Corporation. “Stemtech is proud of Ana’s accomplishments and applauds her efforts to share the benefits of our great products and business opportunity” continued Meyer. “Chairman & CEO Charles Arnold and I both were very happy to call Ana and congratulate her success”, said Meyer. Ana Groenewold has worked with so many, including Stemtech’s Managing Director of Latin Markets, Alejandro Carrillo, who expresses his admiration for Ana’s drive to succeed.
Ana commented that “I wanted a project with the potential to change the world! 9 years ago, I found Stemtech and since then the passion was born in me to not stop for a single day! I love Stemtech, I love my life, I love my great, great team!”
About Stemtech Corporation
Stemtech Corporation, a leading nutraceutical company with a direct sales distribution model, was founded on April 18, 2018, after acquiring the operations from its predecessor Stemtech International, Inc. which was founded in 2005. From 2010 through 2015, Stemtech International, Inc., was recognized four separate times on the Inc. 5000 Fastest-Growing Companies list. In 2018, the Company underwent an extensive executive reorganization, and continued operations under new leadership. Stemtech specializes in creating products and formulas that are patent protected in the U.S. and in select international markets. The Company’s patented formulas help the release, circulation and migration of the body’s adult stem cells from its bone marrow. The Company markets its products under the following brands: RCM System, stemrelease3™
This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-K filed April 1, 2022. We undertake no duty to update any forward-looking statement, or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Stemtech Corporation which are condoned by the Company must emanate from the Company itself and bear our name as its Source.
For Further Information, Contact:
Investors: Frank J. Pena, 908-675-0581, firstname.lastname@example.org